Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Feb;33(2):322-6.
doi: 10.2337/dc09-1380. Epub 2009 Nov 16.

Metformin associated with lower cancer mortality in type 2 diabetes: ZODIAC-16

Gijs W D Landman  1 , Nanne Kleefstra, Kornelis J J van Hateren, Klaas H Groenier, Rijk O B Gans, Henk J G Bilo
Affiliations

Metformin associated with lower cancer mortality in type 2 diabetes: ZODIAC-16

Gijs W D Landman et al. Diabetes Care. 2010 Feb.

Abstract

Objective: Several studies have suggested an association between specific diabetes treatment and cancer mortality. We studied the association between metformin use and cancer mortality in a prospectively followed cohort.

Research design and methods: In 1998 and 1999, 1,353 patients with type 2 diabetes were enrolled in the Zwolle Outpatient Diabetes project Integrating Available Care (ZODIAC) study in the Netherlands. Vital status was assessed in January 2009. Cancer mortality rate was evaluated using standardized mortality ratios (SMRs), and the association between metformin use and cancer mortality was evaluated with a Cox proportional hazards model, taking possible confounders into account.

Results: Median follow-up time was 9.6 years, average age at baseline was 68 years, and average A1C was 7.5%. Of the patients, 570 died, of which 122 died of malignancies. The SMR for cancer mortality was 1.47 (95% CI 1.22-1.76). In patients taking metformin compared with patients not taking metformin at baseline, the adjusted hazard ratio (HR) for cancer mortality was 0.43 (95% CI 0.23-0.80), and the HR with every increase of 1 g of metformin was 0.58 (95% CI 0.36-0.93).

Conclusions: In general, patients with type 2 diabetes are at increased risk for cancer mortality. In our group, metformin use was associated with lower cancer mortality compared with nonuse of metformin. Although the design cannot provide a conclusion about causality, our results suggest a protective effect of metformin on cancer mortality.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Cumulative survival curve for cancer mortality.
Figure 2
Figure 2
Cumulative survival curve for total mortality.
Figure 3
Figure 3
Cumulative survival for cardiovascular mortality.
Figure 4
Figure 4
Cumulative survival for non-cancer and non-cardiovascular (CV) (all other causes) mortality.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Hemkens LG, Grouven U, Bender R, Günster C, Gutschmidt S, Selke GW, Sawicki PT. Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study. Diabetologia 2009; 52: 1732– 1744 - PMC - PubMed
    1. Currie CJ, Poole CD, Gale EA. The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia 2009; 52: 1766– 1777 - PubMed
    1. Calle EE, Murphy TK, Rodriguez C, Thun MJ, Heath CW., Jr Diabetes mellitus and pancreatic cancer mortality in a prospective cohort of United States adults. Cancer Causes Control 1998; 9: 403– 410 - PubMed
    1. Will JC, Vinicor F, Calle EE. Is diabetes mellitus associated with prostate cancer incidence and survival? Epidemiology 1999; 10: 313– 318 - PubMed
    1. Chow WH, Gridley G, Nyrén O, Linet MS, Ekbom A, Fraumeni JF, Jr, Adami HO. Risk of pancreatic cancer following diabetes mellitus: a nationwide cohort study in Sweden. J Natl Cancer Inst 1995; 87: 930– 931 - PubMed

MeSH terms